{
  "symbol": "ABBV",
  "year": 2023,
  "Period": "Q2",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": 0.0,
    "outlook_sentiment": 0.279,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.086
  },
  "top_positive": [
    {
      "sent": "Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency\u00a0rates At\u00a0constant currency rates At\u00a0actual currency\u00a0rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 2023 2022 United States $ 10,720 $ 11,410 (6.0) % (6.0) % $ 19,921 $ 21,758 (8.4) % (8.4) % International 3,145 3,173 (0.9) % 2.6 % 6,169 6,363 (3.0) % 1.8 % Net revenues $ 13,865 $ 14,583 (4.9) % (4.2) % $ 26,090 $ 28,121 (7.2) % (6.1) % 2023 Form 10-Q | 27 The following table details AbbVie\u2019s worldwide net revenues: Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 2023 2022 Immunology Humira United States $ 3,452 $ 4,664 (26.0) % (26.0) % $ 6,400 $ 8,657 (26.1) % (26.1) % International 560 699 (19.8) % (17.0) % 1,153 1,442 (20.1) % (15.9) % Total $ 4,012 $ 5,363 (25.2) % (24.8) % $ 7,553 $ 10,099 (25.2) % (24.6) % Skyrizi United States $ 1,634 $ 1,079 51.4 % 51.4 % $ 2,773 $ 1,860 49.1 % 49.1 % International 249 173 44.2 % 48.6 % 470 332 41.5 % 48.2 % Total $ 1,883 $ 1,252 50.4 % 51.0 % $ 3,243 $ 2,192 48.0 % 49.0 % Rinvoq United States $ 645 $ 412 56.4 % 56.4 % $ 1,094 $ 723 51.2 % 51.2 % International 273 180 52.2 % 57.5 % 510 334 52.9 % 61.0 % Total $ 918 $ 592 55.1 % 56.7 % $ 1,604 $ 1,057 51.7 % 54.2 % Hematologic Oncology Imbruvica United States $ 666 $ 862 (22.8) % (22.8) % $ 1,304 $ 1,736 (24.9) % (24.9) % Collaboration revenues 241 283 (14.7) % (14.7) % 481 582 (17.3) % (17.3) % Total $ 907 $ 1,145 (20.8) % (20.8) % $ 1,785 $ 2,318 (23.0) % (23.0) % Venclexta United States $ 265 $ 253 5.2 % 5.2 % $ 530 $ 481 10.2 % 10.2 % International 306 252 21.0 % 24.9 % 579 497 16.5 % 22.1 % Total $ 571 $ 505 13.1 % 15.0 % $ 1,109 $ 978 13.4 % 16.2 % Aesthetics Botox Cosmetic United States $ 420 $ 449 (6.5) % (6.5) % $ 829 $ 862 (3.8) % (3.8) % International 265 246 7.9 % 13.8 % 515 474 8.7 % 15.7 % Total $ 685 $ 695 (1.4) % 0.7 % $ 1,344 $ 1,336 0.6 % 3.1 % Juvederm Collection United States $ 125 $ 147 (14.5) % (14.5) % $ 247 $ 295 (16.2) % (16.2) % International 243 197 22.8 % 27.6 % 476 459 3.6 % 11.1 % Total $ 368 $ 344 6.9 % 9.7 % $ 723 $ 754 (4.1) % 0.4 % Other Aesthetics United States $ 284 $ 287 (1.3) % (1.3) % $ 530 $ 572 (7.4) % (7.4) % International 47 45 6.8 % 12.0 % 87 83 5.3 % 12.3 % Total $ 331 $ 332 (0.2) % 0.5 % $ 617 $ 655 (5.8) % (4.9) % Neuroscience Botox Therapeutic United States $ 614 $ 557 10.1 % 10.1 % $ 1,201 $ 1,057 13.6 % 13.6 % International 134 121 10.7 % 17.0 % 266 235 13.0 % 20.4 % Total $ 748 $ 678 10.2 % 11.3 % $ 1,467 $ 1,292 13.5 % 14.9 % Vraylar United States $ 657 $ 492 33.7 % 33.7 % $ 1,217 $ 919 32.5 % 32.5 % International 1 \u2014 >100.0 % >100.0 % 2 \u2014 >100.0 % >100.0 % Total $ 658 $ 492 33.9 % 33.9 % $ 1,219 $ 919 32.7 % 32.7 % Duodopa United States $ 24 $ 26 (7.6) % (7.6) % $ 49 $ 50 (0.8) % (0.8) % International 93 94 (1.6) % (0.5) % 186 191 (3.0) % 0.6 % Total $ 117 $ 120 (2.9) % (2.0) % $ 235 $ 241 (2.5) % 0.3 % Ubrelvy United States $ 194 $ 185 4.5 % 4.5 % $ 344 $ 323 6.4 % 6.4 % International 2 \u2014 n/m n/m 4 \u2014 n/m n/m Total $ 196 $ 185 5.9 % 6.0 % $ 348 $ 323 7.7 % 7.7 % Qulipta United States $ 95 $ 33 >100.0 % >100.0 % $ 161 $ 44 >100.0 % >100.0 % International 1 \u2014 n/m n/m 1 \u2014 n/m n/m Total $ 96 $ 33 >100.0 % >100.0 % $ 162 $ 44 >100.0 % >100.0 % Other Neuroscience United States $ 65 $ 145 (55.9) % (55.9) % $ 140 $ 318 (56.3) % (56.3) % International 5 5 4.7 % 11.4 % 9 9 5.7 % 12.0 % Total $ 70 $ 150 (53.8) % (53.6) % $ 149 $ 327 (54.6) % (54.4) % 2023 Form 10-Q | 28 Three months ended June 30, Percent\u00a0change Six months ended June 30, Percent\u00a0change At\u00a0actual currency rates At\u00a0constant currency rates At\u00a0actual currency rates At\u00a0constant currency rates (dollars in\u00a0millions) 2023 2022 2023 2022 Eye Care Ozurdex United States $ 34 $ 36 (3.3) % (3.3) % $ 73 $ 69 6.3 % 6.3 % International 85 74 14.2 % 16.6 % 161 148 8.7 % 13.4 % Total $ 119 $ 110 8.6 % 10.2 % $ 234 $ 217 8.0 % 11.2 % Lumigan/Ganfort United States $ 51 $ 60 (13.1) % (13.1) % $ 114 $ 127 (9.7) % (9.7) % International 68 70 (3.9) % (1.1) % 135 143 (5.6) % (1.9) % Total $ 119 $ 130 (8.1) % (6.6) % $ 249 $ 270 (7.5) % (5.5) % Alphagan/Combigan United States $ 32 $ 54 (41.7) % (41.7) % $ 60 $ 124 (51.8) % (51.8) % International 33 38 (13.3) % (8.6) % 76 75 1.4 % 7.4 % Total $ 65 $ 92 (29.7) % (27.7) % $ 136 $ 199 (31.7) % (29.4) % Restasis United States $ 82 $ 151 (45.8) % (45.8) % $ 161 $ 386 (58.4) % (58.4) % International 17 17 (0.7) % 5.2 % 30 28 7.3 % 12.8 % Total $ 99 $ 168 (41.1) % (40.5) % $ 191 $ 414 (54.0) % (53.6) % Other Eye Care United States $ 110 $ 106 1.9 % 1.9 % $ 220 $ 197 11.3 % 11.3 % International 105 111 (4.1) % \u2014 % 195 191 2.1 % 7.0 % Total $ 215 $ 217 (1.1) % 1.0 % $ 415 $ 388 6.8 % 9.2 % Other Key Products Mavyret United States $ 193 $ 203 (5.0) % (5.0) % $ 364 $ 372 (2.2) % (2.2) % International 194 195 (0.9) % 1.9 % 387 406 (4.7) % (0.1) % Total $ 387 $ 398 (3.0) % (1.6) % $ 751 $ 778 (3.5) % (1.1) % Creon United States $ 282 $ 318 (11.4) % (11.4) % $ 587 $ 605 (3.0) % (3.0) % Linzess/Constella United States $ 269 $ 247 8.6 % 8.6 % $ 520 $ 480 8.1 % 8.1 % International 9 8 26.7 % 31.1 % 17 15 19.1 % 24.3 % Total $ 278 $ 255 9.1 % 9.2 % $ 537 $ 495 8.5 % 8.7 % All other $ 741 $ 1,009 (26.4) % (25.3) % $ 1,432 $ 2,220 (35.5) % (34.5) % Total net revenues $ 13,865 $ 14,583 (4.9) % (4.2) % $ 26,090 $ 28,121 (7.2) % (6.1) % n/m \u2013 Not meaningful The following discussion and analysis of AbbVie\u2019s net revenues by product is presented on a constant currency basis.",
      "score": 0.9968
    },
    {
      "sent": "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also reducing debt.",
      "score": 0.986
    },
    {
      "sent": "Reents, evaluated the effectiveness of AbbVie's disclosure controls and procedures as of the end of the period covered by this report, and concluded that AbbVie's disclosure controls and procedures were effective to ensure that information AbbVie is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by AbbVie in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to AbbVie's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.",
      "score": 0.93
    }
  ],
  "top_negative": [
    {
      "sent": "Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected.",
      "score": -0.8779
    },
    {
      "sent": "These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake.",
      "score": -0.7506
    },
    {
      "sent": "AbbVie\u2019s management, including its Chief Executive Officer and its Chief Financial Officer, do not expect that AbbVie\u2019s disclosure controls or internal control over financial reporting will prevent or detect all errors and all fraud.",
      "score": -0.7269
    }
  ],
  "forward_snippets": [
    "AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches; (iii)\u00a0continuing to invest in and expand its pipeline in support of opportunities in immunology, oncology, aesthetics, neuroscience and eye care as well as continued investment in key on-market products; (iv)\u00a0generating substantial operating cash flows to support investment in innovative research and development, and return cash to shareholders via a strong and growing dividend while also reducing debt.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "AbbVie\u2019s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care.",
    "Additionally, financial results reflected continued funding to support all stages of AbbVie\u2019s pipeline assets and continued investment in AbbVie\u2019s on-market brands.",
    "AbbVie\u2019s pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements and is focused on such important specialties as immunology, oncology, aesthetics, neuroscience and eye care."
  ]
}